Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00706355 · ClinicalTrials.gov registry record · Phase 1
A Study of PF-04217903 in Patients With Advanced Cancer
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00706355 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 16 participants.
The verdict
NCT00706355, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
PF-04217903 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-04217903 is a new member in a class of drugs called c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitors. This research study is the first time PF-04217903 will be given to patients. PF-04217903 is taken by mouth daily.
Interventions
- DRUG PF-04217903
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-08 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00706355
The ClinicalTrials.gov registry entry for NCT00706355 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-04217903 is the first listed.
NCT00706355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00706355 about?
NCT00706355 is a clinical study titled "A Study of PF-04217903 in Patients With Advanced Cancer". PF-04217903 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-04217903 is a new member in a class of drugs called c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitors. This research study is the first time PF-04217903 will be given to patients. P...
What is the current status of trial NCT00706355?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2008-08. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00706355?
The interventions under investigation include: PF-04217903 (DRUG).
Who is sponsoring clinical trial NCT00706355?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.